STAT protein family and cardiovascular diseases: overview of pathological mechanisms and therapeutic implications

Ghader Babaei1, Samin Sadraei2, Maral Yarahmadi3

  • 1Department of Clinical Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

PubMed

Insights

Cardiovascular diseases (CVD) are a major global health concern. This review explores how signal transducer and activator of transcription (STAT) pathways contribute to CVD pathogenesis and their potential as therapeutic targets.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Cardiology

Background:

  • Cardiovascular diseases (CVD) represent a significant global health burden and a primary cause of mortality.
  • Understanding the molecular mechanisms underlying CVD pathogenesis is a critical scientific objective.
  • The signal transducer and activator of transcription (STAT) signaling pathway is implicated in diverse physiological and pathological processes.

Purpose of the Study:

  • To elucidate the intricate relationship between STAT signaling pathways and the development of cardiovascular diseases.
  • To review the current evidence highlighting the role of STAT proteins in various CVDs.
  • To explore the therapeutic potential of targeting STAT signaling pathways for CVD treatment.

Main Methods:

  • Literature review of studies investigating STAT signaling in cardiovascular disease.
  • Analysis of molecular mechanisms linking STAT pathways to CVD pathogenesis.
  • Synthesis of research findings on the relevance of STAT family proteins in different CVDs.

Main Results:

  • STAT signaling pathways are demonstrably involved in the molecular mechanisms of cardiovascular diseases.
  • STAT family proteins play a crucial role in the pathogenesis of various CVDs.
  • Evidence supports the significant relevance of STAT proteins in numerous cardiovascular conditions.

Conclusions:

  • STAT signaling pathways are integral to the development and progression of cardiovascular diseases.
  • Targeting STAT signaling pathways presents a promising therapeutic strategy for managing CVD.
  • Further research into STAT pathways could unlock novel treatments for cardiovascular conditions.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
645
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K